United States Natural Gas Fund vs Vir Biotechnology Inc. Common Stock — how do they compare? United States Natural Gas Fund trades at $11.2 (market cap $503.45M), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Vir Biotechnology Inc. Common Stock is far larger — about 3.6× United States Natural Gas Fund's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Natural Gas Fund for 23 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| UNG | VIR | |
|---|---|---|
Market Cap | $503.45M | $1.80B |
Volume | 27,352,527 | 1,782,836 |
Sector | Commodities - Energy | Health |
52-Week High | $16.90 | $11.78 |
52-Week Low | $9.63 | $5.12 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $1.36B |
Signals from Pluang's Aura AI — not financial advice
UNG trades at $11.41, up 4.49% today, with a bullish technical signal from moving averages. The fund shows strong net income of $65.15M for 2024 despite zero revenue, supported by $593.54M in cash. Recent news highlights natural gas market volatility, with record U.S. production and geopolitical tensions influencing prices.
Outlook: Bullish technicals and solid liquidity offer upside, but reliance on natural gas price swings and zero revenue pose risks. Investors should weigh energy market stability against the fund's cash position and income generation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →